Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195698 · ClinicalTrials.gov registry record · Phase 3
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 475
- Enrollment target
NCT04195698 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 475 participants.
The verdict
NCT04195698, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 475 participants
- Enrollment target
Study Summary
This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 30 day follow-up visit after the treatment period is completed. Main objective of this study is to assess long-term safety, tolerability and efficacy of upadacitinib in participants with moderate to severe atopic dermatitis who successfully completed treatment in the study M16-046.
Interventions
- DRUG Upadacitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 475 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2023-09-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04195698
The ClinicalTrials.gov registry entry for NCT04195698 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 475 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib is the first listed.
NCT04195698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04195698 about?
NCT04195698 is a clinical study titled "Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis". This is a study for adults (18-75 years) who have successfully completed treatment either with Dupilumab or with Upadacitinib in the study M16-046. At the end of M16-046, they have the option to receive Upadacitinib with a duration of 52 weeks beyond the timeframe of Study M16-046. There will be a 3...
What is the current status of trial NCT04195698?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 475 participants. The study started on 2020-01-15. Estimated completion is 2023-09-11.
What interventions are being tested in trial NCT04195698?
The interventions under investigation include: Upadacitinib (DRUG).
Who is sponsoring clinical trial NCT04195698?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.